Overcoming multi-drug resistance using an intracellular anti-MDR1 sFv

International Journal of Cancer

Volumn 92, Issue 1, 2001, Pages 115-122

  Heike, Yuji ^a,b,c   Kasono, Keizo ^a   Kunisaki, Chikara ^a   Hama, Seiji ^c   Saijo, Nagahiro ^b   Tsuruo, Takashi ^d   Kuntz, Douglas A ^e   Rose, David R ^e   Curiel, David T ^a  

^a UAB Gene Therapy Center   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adriamycin; Functional knockout; Multidrug resistance; Single chain antibody

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123;

ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CONTROLLED STUDY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

EID: 0035313983     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1150>3.0.CO;2-W     Document Type: Article

References (40)

1. Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance
2. Expression of a multidrug-resistance gene in human tumors and tissues
3. Detection of multidrug resistance markers. P-glycoprotein and mdr1 mRNA, in human leukemia cells
4. Characterization of the ATPase activity of the 170- to 180-kDa membrane glycoprotein (P-glycoprotein) associated with multidrug resistance
5. Purification of the 170- to 180-kDa membrane glycoprotein associated with multidrug resistance. 170- to 180-kDa membrane glycoprotein is an ATPase
6. Experimental model systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches
7. Reversal of Adriamycin resistance by verapamil in human ovarian cancer
8. Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients
9. Phase I crossover study of pacritaxel with r-verapamil in patients with metastatic breast cancer
10. Randomized trial of verapamil in addition to chemotherapy for small cell lung cancer
11. Clinical trials of agents that reverse multidrug-resistance
12. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas
13. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides
14. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides
15. Retrovirus mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: Screening for effective target sites
16. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo
17. Functional knock-out of c-myb by an intracellular anti-c-Myb single-chain antibody
18. The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv
19. Intracellular expression of the anti-erbB-2 sFv N29 fails to accomplish efficient target modulation
20. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7
21. Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody
22. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug-resistance
23. Efficient inhibition of p-glycoproteinmediated multidrug resistance with a monoclonal antibody
24. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
25. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies
26. A single chain Fv fragment of P-glycoprotein-specific monoclonal antibody C219. Design, expression, and costal structure at 2.4 A resolution
27. Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein
28. Characteristics of resistance to Adriamycin in human myelogenous leukemia K562 resistant Adriamycin and in isolated clones
29. Growth inhibition of multidrug-resistant cells by monoclonal antibodies against P-glycoprotein
30. Monoclonal antibody-dependent killing of multidrug-resistant tumor cells by human mononuclear cells
31. Systematic therapy of metastatic renal cell carcinoma
32. ATP-binding properties of P-glycoprotein from multidrug-resistant KB cells
33. Characterization for the multidrug resistance protein expressed in cell clones stably transfected with the mouse MDR1 cDNA
34. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects
35. Modulation of ATP and drug binding by monoclonal antibodies against P-glycoprotein
36. Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein
37. Antibodies for targeted gene therapy: Extracellular a gene targeting and intracellular expression
38. Cross-reactivity of C219 anti-p170mdr-1 antibody with p185c-erbB2 in breast cancer cells: Cautions of evaluating p170mdr-1
39. P-glycoprotein of blood brain barrier: Cross-reactivity of Mab C219 with a 190 kDa protein in bovine and rat isolated brain capillaries
40. Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: Diagnostic and clinical implications